Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 2
Background on Colorectal Cancer Screening and its Role in Patient Care
Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.
- Dr Dasari: Please describe the importance and a brief history of CRC screening
- What are some challenges traditionally associated with CRC screening?
- Do these challenges vary between academic and community settings?
- How have noninvasive screening methods and age recommendations evolved over time?
- Please briefly mention the variety of sources (stool, blood, tissue, etc.) and methods that have become available
- What are some challenges traditionally associated with CRC screening?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
